Keryx Biopharmaceuticals buy melinda
Start price
11.09.18
/
50%
€2.80
Target price
27.09.18
€2.98
Performance (%)
7.10%
End price
27.09.18
€2.99
Summary
This prediction ended on 27.09.18 with a price of €2.99. The BUY prediction by melinda finished with a performance of 7.10%. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Keryx Biopharmaceuticals | - | - | - | - |
iShares Core DAX® | -1.414% | 7.218% | 17.151% | 15.732% |
iShares Nasdaq 100 | -2.316% | 4.450% | 18.360% | 30.945% |
iShares Nikkei 225® | -2.756% | 10.071% | 10.704% | 2.733% |
iShares S&P 500 | -1.849% | 4.760% | 19.639% | 34.852% |
Comments by melinda for this prediction
In the thread Keryx Biopharmaceuticals diskutieren
SecteurRecherche biotechnologique et médicale Agenda 07/11 Publication de résultats
Operates as a biopharmaceutical company which focuses on therapies for patients with renal disease
Keryx Biopharmaceuticals, Inc. engages in the manufacture, development, and commercialization of medicines for use in treating human diseases.
Its product is the Auryxia tablet.
The company was founded in October 1998 and is headquartered in Boston, MA.
Keryx Biopharmaceuticals, Inc. engages in the manufacture, development, and commercialization of medicines for use in treating human diseases.
Its product is the Auryxia tablet.
The company was founded in October 1998 and is headquartered in Boston, MA.
Nombre d'employés : 210 personnes.
(Zielkurs erreicht)
Stopped prediction by melinda for Keryx Biopharmaceuticals
Keryx Biopharmaceuticals
Start price
Target price
Perf. (%)
€5.97
20.06.13
20.06.13
€7.50
20.12.13
20.12.13
58.49%
20.12.13
20.12.13
Keryx Biopharmaceuticals
Start price
Target price
Perf. (%)
€2.98
15.07.10
15.07.10
€8.00
28.09.10
28.09.10
18.12%
28.09.10
28.09.10